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-Synuclein (aS) is a protein abundant in presynaptic nerve
terminals in Parkinson disease (PD) and is a major component
of intracellular Lewy bodies, the pathological hallmark of
neurodegenerative disorders such as PD. Accordingly, the
relationships between aS structure, its interaction with lip-
ids, and its involvement in neurodegeneration have attracted
great interest. Previously, we reported on the interaction of
aS with brain polyunsaturated fatty acids, in particular doco-
sahexaenoic acid (DHA). aS acquires an -helical secondary
structure in the presence of DHA and, in turn, affects DHA
structural and aggregative properties. Moreover, aS forms a
covalent adduct with DHA. Here, we provide evidence that
His-50 is the main site of this covalent modification. To better
understand the role of His-50, we analyzed the effect of DHAon
aS-derived species: a naturally occurring variant, H50Q; an oxi-
dized aS in which all methionines are sulfoxides (aS4ox); a fully
lysine-alkylated aS (acetyl-aS); and aS fibrils, testing their ability
to be chemicallymodified byDHA.We show, bymass spectrom-
etry and spectroscopic techniques, that H50Q and aS4ox are
modified by DHA, whereas acetyl-aS is not. We correlated this
modification with aS structural features, and we suggest a pos-
sible functional role of aS in sequestering the early peroxidation
products of fatty acids, thereby reducing the level of highly reac-
tive lipid species. Finally, we show that fibrillar aS loses almost
80% of its scavenging activity, thus lacking a potentially protec-
tive function. Our findings linking aS scavenging activity with
brain lipid composition suggest a possible etiological mecha-
nism in some neurodegenerative disorders.
-Synuclein (aS)3 is a cytosolic protein abundant in presyn-
aptic nerve terminals involved in the pathogenesis of Parkinson
disease (PD). It is amajor component of intracellular Lewy bod-
ies, the pathological hallmarks of neurodegenerative disorders
such as PD and Lewy body dementia (1). Several point muta-
tions in aS gene (SNCA) and copy number gains have been
found to lead to PD (2–5). Structurally, aS is classified as a
natively unfolded protein, being disordered in solution (6). Its
sequence is generally considered as consisting of three major
domains (Fig. 1). The N-terminal, residues 1–60, contains four
of the seven imperfect 11 amino acids repeats sharing simi-
larity to lipid binding domains of apolipoproteins, and acquires
helical conformation upon binding to lipids andmembranes (7,
8). The central region, residues 61–95, non-A component
(NAC), has a critical role for nucleation of the aggregation
process (9). The C-terminal, enriched in acidic residues and
prolines, is highly hydrophilic, and able to establish transient
interactions with the N-terminal or other proteins (10). aS
physiological function is not yet fully defined, but several stud-
ies correlate the protein with membranes and lipids for its abil-
ity to remodel membranes (11), to influence the lipid packing
(12), or to regulate the synaptic vesicle fusion (13, 14).
Previous reports documented the ability of aS to interact
with brain polyunsaturated fatty acids (PUFAs), which are crit-
ical for neuronalmembranes, fluidity, and permeability, serving
as an energy reservoir, and taking part in intra- and extracellu-
lar signaling as second messengers (15). PUFAs mediate other
functions such as generation of apoptotic signals, cellular pro-
liferation, and translocation of lipid-modifying enzymes to
cellular membranes (15). Docosahexaenoic (DHA, 22:6) and
arachidonic (AA, 20:4) acids are the most abundant fatty acids
in the brain. DHA is a n-3 fatty acid containing six double
bonds, whereas AA is a n-6 fatty acid with four double bonds,
therefore they are highly susceptible to oxidation. They can be
oxidized enzymatically and non-enzymatically through a free
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radical-mediated mechanism (16–18). Each oxidation mecha-
nism yields specific products, in particular hydroperoxides,
hydroxide positional isomers, and free radicals that are highly
reactive (19). The relative susceptibility of PUFAs to oxidation
depends on the reaction milieu as well as their inherent struc-
ture. The biological role of PUFA peroxidation products has
received a great deal of attention because when it was discov-
ered that ,-unsaturated aldehydes, the advanced lipid per-
oxidation end products, can react with sulfhydryl groups of
proteins, forming stable adducts able to affect severalmetabolic
processes (20).
Lipid peroxidation is involved in several humandiseases such
as atherosclerosis, cancer, diabetes, acute lung injury, as well as
neurodegenerative disorders including PD (21), Huntington
disease (22), andAlzheimer disease (23). Therefore, efforts have
been devoted to understanding the mechanism of lipid peroxi-
dation and preventing the deleterious effects of this process.
Interestingly, it was shown that 4-hydroxy-2-nonenal (4HNE),
a product of lipid peroxidation, forms protein adducts in Lewy
bodies in neocortical and brain neurons (24). 4HNE was also
found to alter dopamine transport, contributing to the loss of
dopamine, which is a feature of PD (25). In this scenario, the
correlation between aS and PUFAs has raised considerable
interest.
The consequences of aS ability to interact with PUFAs are
immediately ascertainable on its structure, because the protein
undergoes conformational transition in the presence of fatty
acids containing unsaturations (26, 27). It seems that the 1–70
region of aS ismainly involved in themolecular interactionwith
the fatty acid (27). We, in particular, showed that aS in the
presence of DHA acquires -helical secondary structure and
forms, upon incubation, toxic oligomers able to affect mem-
brane permeability (27, 28). The mutual effect between DHA
and aS is strongly determined by the protein/lipid ratio. Fur-
thermore, the protein undergoes chemical modifications, such
as the formation of a covalent adduct with DHA, methionine
(Met) residue oxidation, and carbonylation (29). The four Met
residues (Met-1, Met-5, Met-116, and Met-127) are easily oxi-
dized to sulfoxide and this phenomenon plays an important
role in modulating aS membrane binding and aggregation (30).
Methionine sulfoxide reductase reverses oxidized aS suggesting
that the protein can contribute to the protection of membrane
from oxidative damage (31). Moreover, it was observed that
4HNE formed under strong oxidative stress conditions can
covalentlybindaS, triggering the formationof-sheet-richolig-
omers (32). However, the relationship between aS structure, its
binding to PUFAs, and the role of the chemical modification, is
still not clear. It was proposed that aSmay act physiologically as
a catalytically regenerated scavenger of oxidants in healthy cells
(33).
In the present work, we show by mass spectrometry analysis
that the early radical products of DHA and AA autoxidation
reactwith aS, producing a covalentmodification on the protein.
Histidine (His) at position 50 seems to be the major target of
this reaction and the four Met are oxidized. To understand if
the role ofHis would be specific in this sort of scavenger activity
of free radicals, we analyzeDHA in the presence of a pathogenic
aS variant presenting the H50Q missense mutation (34–36).
Then we evaluated a possible contribution of Met residues by
using a completely oxidized aS and to understand the role of the
7 imperfect 11-residue repeats domain, all lysine (Lys) residues
were acetylated. Finally, for a correlation with the aggregation
state of aS, DHA was also analyzed in the presence of aS fibrils.
Our in vitro data suggest that aS might be able to exert a
sequestering/scavenging activity versusDHAandAA early rad-
ical autoxidation products that is modulated by different fac-
tors. First, the mutual structural interaction between aS and
PUFAs is an essential prerequisite for this activity, because it
provides a stabilizing effect on the fatty acid physical state. Sec-
ond, His and Lys collaborate in sequestering the early peroxi-
dation products. In this way, the propagation of the oxidative
process of fatty acids is hampered, and concentration of the
highly reactive species is reduced.
Results
DHA and AA autoxidation process
DHA and AA samples were incubated at pH 7 and 37 °C
under shaking up to 24 h, in the absence and presence of aS
(P/lipid molar ratio 1:50). Aliquots from DHA samples were
analyzed by direct injection in electrospray ionization (ESI)-MS
(Fig. 2). The ESI-MS spectrum of DHA just after its solubiliza-
tion is reported in Fig. 2A. It presents a specific pattern of sev-
eral signals (37): the most peculiar are those at mass/charge
values of 329.2, 351.2, and 367.2 corresponding to a protonated
molecular DHA (monoisotopic mass 328.2 Da), an adduct with
sodium (328.2 Da  22), and an oxidized form of this adduct
(328.2 Da  22  16). Moreover, other minor signals due to
in-cone fragmentation (m/z 311.2, 269.2) are also visible. After
24 h of incubation (Fig. 2B), the signals atm/z 329.2, 351.2, and
367.2, characteristics of DHA, disappear and new species are
evident in the spectrum atm/z values of 381.3, 397.2, and 415.2
corresponding to hydroperoxide derivatives of DHA, which
generate during the propagation phase of the fatty acids autox-
idation (Scheme 1). The species atm/z 415.2 is themost intense
signal and it has been identified by MS-MS analysis, as a di-
hydroperoxide derivative of DHA (Table 1). Then the fatty acid
was incubated in the presence of aS recording the mass spectra
up to 24 h (Fig. 2D). The 24-h spectrum is quite similar to that
obtained at time 0 (Fig. 2, A and C) and the oxidized species do
not form in the presence of the protein. As control, DHA upon
Figure 1. Amino acid sequence of aS. Schematic representation of the aS
sequence highlighting methionine, lysine, and histidine residues in red, blue,
and green, respectively (top). Scheme of the three major domains of the pro-
tein: the N-terminal region involved in lipid andmembrane binding, the NAC
domain (61–95) responsible for aggregation properties of the protein, and
the acidic C-terminal region, able to transiently interact with the N-terminal
and the NAC domainsmodulating the aggregation propensity of the protein
(bottom).
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24 h at 37 °C in the presence of aS added immediately before the
MS analysis, was analyzed to show that the higher molecular
weight DHA species are still detectable.
The same experimentwas conducted usingAAas a fatty acid.
In Fig. 2E, the m/z spectrum of AA is reported, where the sig-
nals corresponding tomolecular AA, its sodium adduct, and its
hydroxyl form are evident (m/z 305.3, 327.3, and 343.3). Also
the products of partial degradation of AA (37) at m/z 259.2,
269.2, and 287.2 are visible. After 24 h of incubation, AA forms
several species including the di-hydroperoxy derivative (m/z
391.3), a sign of autoxidation process (Fig. 2F). In Fig. 2, G and
H, the same spectra are recorded in the presence of aS, showing
that in this case the early autoxidation products do not form
within 24 h of incubation with the protein. In Table 1, the spe-
cies of DHA and AA identified by MS analysis are listed.
Chemical modification of aS
The mass analysis of aS samples analyzed in the presence of
DHA or AA are reported in Table 2. In particular, species con-
taining oxidations (16 Da or multiple of 16) and covalent
adductswithDHA (326Da) orAA (304Da) are present. For
the purpose of the present work, the samples were analyzed
only up to 24 h of incubation, because aS aggregates and forms
oligomers upon prolonged incubation in the presence of fatty
acids, as previously observed, and other modifications can
occur (29).
To identify the site of modification in the aS sequence, fin-
gerprinting analysis by trypsin and endoproteinase GluC was
performed. These proteases selectively cleave the peptide
bonds involving basic and glutamic acid residues, respectively
(Fig. 3). A RP-HPLC fraction enriched of the chemically modi-
fied aS with DHA was digested by trypsin, using an enzyme to
substrate ratio (E/S) of 1:100, or by GluC, using an E/S of 1:50.
Table 1
DHA and AA products identified in their ESI spectra obtained in the
absence and in the presence of aS (Fig. 2)
MH Species Description
329.2 DHA (C22H32O2) Docosahexaenoic acid (monoisotopic
mass 328.2)
351.2 DHA Na Sodium adduct of DHA
367.2 DHAOHNa Sodium adduct of hydroxy DHA
381.3 DHAOO Na Sodium adduct of peroxy radical DHA or
DHA(O)2 Na Sodium adduct of dialkoxy radical DHA
397.2 DHA(OO)(O) Na Sodium adduct of alkoxy-peroxy diradical DHA
415.2 DHA(OOH)2 Na Sodium adduct of dihydroperoxy DHA
305.3 AA (C20H32O2) Arachidonic acid (monoisotopic mass 304.2)
327.3 AA Na Sodium adduct of AA
343.3 AAOHNa Sodium adduct of hydroxy AA
349.3 AA 2Na Di-sodium adduct of AA
373.3 AA(OOH)2 Na 18 Sodium adduct of dihydroperoxy AA
dehydrated
391.3 AA(OOH)2 Na Sodium adduct of dihydroperoxy AA
413.3 AA(OOH)2 2Na Di-sodium adduct of dihydroperoxy AA
Table 2
Molecular masses of aS after incubation in the presence of DHA or AA
PUFA
Molecular mass (Da)
Protein speciesFounda Calculatedb
14459.9 (0.1) 14460.1 aS
14475.7 (0.8) 14476.1 aS 1ox
14492.2 (0.1) 14492.1 aS 2ox
14508.3 (0.1) 14508.1 aS 3ox
DHA 14802.2 (0.1) 14802.1 aS 1ox 326
14817.1 (0.7) 14818.1 aS 2ox 326
14835.3 (0.5) 14834.1 aS 3ox 326
14849.9 (0.7) 14850.1 aS 4ox 326
14865.2 (0.9) 14866.1 aS 3ox 358
14880.8 (0.9) 14882.1 aS 4ox 358
AA 14747.2 (1.4) 14746.1 aS 286
14765.1 (0.8) 14764.1 aS 304
14781.2 (0.9) 14780.1 aS 1ox 304
14794.8 (0.5) 14796.1 aS 2ox 304
a Experimental molecular masses determined by ESI-MS.
bMasses calculated from the amino acid sequence of aS.
Figure 2. Mass/charge spectra of DHA and AA. Positive ESI-MS of DHA
(A–D) and AA (E and F), recorded just after the preparation of the samples (A
and E) and upon 24 h at 37 °C and 300 rpm (B and F). The same samples were
analyzed in the presence of aS (P/lipid 1:50) at 0 h (C and G) and after 24 h of
incubation (D and H). B, inset: as control, DHA upon 24 h at 37 °C in the pres-
ence of aS added immediately before the MS analysis. The spectra were
obtained at2.5 kV of capillary and a cone voltage of 35 V.
Scheme 1. Mechanism of non-enzymatic free-radical mediated oxida-
tion of unsaturated lipids. These chain reactions, described in terms of ini-
tiation (1), propagation (2), and termination (3), are also defined lipid autoxi-
dation process (19). The initiation is induced by thermolysis, metal catalysis,
or photolysis. Symbols here used: FAH, fatty acid; FA, fatty acid radical;
FAOO, peroxyl radical, FAOOH, hydroperoxides; FAO, alkoxy radical; HO,
hydroxy radical.
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The proteolytic fragments were purified by RP-HPLC (Fig. 3,A
and B) and identified by MS (Tables 3 and 4). In the tryptic
mixture, fragments 1–6, 1–60, 81–140, and 98–140, contain-
ing Met residues are present also in oxidized form (16 Da),
whereas fragments corresponding to sequences 1–60, 35–80,
46–80, and 46–58 were found with a mass increase of 326 Da.
The residues, susceptible of modification, present in all the
detectedmodified peptides areHis andLys.His as a nucleophile
is stronger than Lys, and it is consequently more prone to be
modified. To confirm this hypothesis, MS-MS analysis of
the modified fragments was performed. In Fig. 3C, the MS-MS
spectrum of the peptide-(46–58) 326, the shortest modified
peptide, is reported. The analysis was conducted on its double
charged ion atm/z 811.4. The spectrum does not show signals
relative to the series of y- or b-ions, but products of partial
degradation (m/z 754.33, 762.95, and 781.89) together with a
strong ion at m/z 648.39 corresponding to the double charged
ion of the peptide-(46–58) without the covalent adduct (Fig.
3C). The species at m/z 781.89 is particularly interesting,
because it is produced for removal of the moiety CH2COOH
(59 Da), partially confirming the identity of the modified pep-
tide. From the other hand, it was not possible to obtain direct
evidence of which specific amino acid has reacted with the fatty
acid, because the energy used for the collision of the double
charged ions produces ions corresponding to the peptide with-
outmodification (m/z 648.39). Indeed, theMS-MS spectrum of
the ion atm/z 648.39 confirms the identity of the peptide (Fig.
3D). In the proteolytic mixture of modified aS with DHA by
GluC, an increase of 326 Da was found on the mass of peptides
corresponding to 36–61 and 29–57 after a 5-min reaction
(data not shown) and to 47–57 after a 70-min reaction (Fig. 3B,
Table 4). This last peptide, which does not contain Lys, provides
direct evidence that His-50 ismodified, even if, also in this case,
a MS-MS spectrum was not obtained. Moreover, no fragments
containing only Lys (and not His) were found modified.
Interaction of H50Q, aS-4ox, and acetyl-aS with DHA
To understand the specific role of His as a site of modifica-
tion of aS in the presence of fatty acids, the interaction with
DHA was studied testing the variant in which the only His res-
idue in position 50 is replaced by Gln. The role of Met was
scrutinized by using aS with oxidized Met (tetraoxidized aS,
aS4ox). Acetylationwas used to abrogate the effect of the 15 Lys
(acetyl-aS). In Fig.4, them/z spectra of DHA after 24 h of incu-
bation in the presence of these three aS species are reported.
They show that DHA early autoxidation products are not pres-
ent if the fatty acid is incubated with H50Q (Fig. 4A) and aS4ox
(Fig. 4B), which in turn are chemically modified by DHA and
Figure 3. Site of chemical modification in aS. Identification of His-50 as the preferential site of chemical modification of aS in the presence of DHA.
Fingerprinting analysis of chemically modified aS/DHA sample by trypsin (A) and endoprotease GluC (B). The analysis was conducted on a Vydac C18 column
(4.6 250 mm; The Separations Group, Hesperia, CA), eluted with a gradient of water, 0.1% TFA versus acetonitrile, 0.085% TFA from 5 to 25% in 5 min, from
25 to28% in13min, from28 to39% in3min, and from39 to45% in21minat a flow rateof 1ml/min. Thenumbers close to thepeaks refer to themainproteolytic
fragments. The fragments containing the chemical modification are highlighted. MS-MS analysis of the double charged ion at 811.4 m/z corresponding to
peptide-(46–58) containing the covalent modification (C). MS-MS analysis of the double charged ion at 648.4m/z corresponding to the peptide-(46–58) (D).
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form covalent adducts (Table 5). On the contrary, in the pres-
ence of acetyl-aS, the autoxidation of DHA is not prevented
(Fig. 4C) and, in the corresponding spectrum, the species atm/z
415.3, indicative of the formation of the di-hydroperoxide
derivative of DHA, is visible and is the most intense signal.
The mass values of aS species measured in the presence of
DHA are reported in Table 5. Several species of acetyl-aS are
observable in its mass spectrum, due to the fact that there are
molecules inwhichnot all the 15Lys residues are acetylated and
species also containing theN-terminal residue acetylated ( 16
acetyl). There is no presence of adduct with DHA.
In the case of H50Q more than one adduct was found, indi-
cating that His is not the only one possible modification site.
Indeed, after His, also Lys are residues highly prone to be mod-
Figure 4. Mass/charge spectra of DHA in the presence of H50Q, aS4ox,
and acetyl-aS. Positive ESI-MS spectra of DHA recorded upon incubation for
24hat 37 °Cand300 rpm in thepresenceofH50Q (A), tetraoxidizedaS (aS4ox,
B), and alkylated aS (acetyl-aS, C). Proteins were added to realize a protein/
lipid ratio of 1:50.Measurements are conducted as described in the legend to
Fig. 2.
Table 3
Chemical characterizationof fragments corresponding to thepeaksof
the chromatogram relative to the fragmentation of aS/DHAwith tryp-
sin shown in Fig. 3A
RTa
Molecular mass (Da)
Peptide speciesdFoundb Calculatedc
min
11.2 830.43 (0.01) 829.91 24–32
13.2 1294.99 (0.05) 1294.68 46–58
1524.16 (0.01) 1523.74 44–58
1620.8 (0.1) 1621.46 46–58 326
1754.37 (0.02) 1754.02 44–60
13.8 1179.93 (0.05) 1179.65 35–45
1406.9 (0.1) 1408.69 33–45
14.1 785.88 (0.11) 785.98 1–6 1ox
801.78 (0.12) 801.98 1–6 2ox
950.7 (0.1) 950.09 35–43
14.7 2157.17 (0.04) 2157.45 59–80
14.9 769.88 (0.1) 769.98 1–6
1607.16 (0.01) 1606.84 81–97
15.1 2148.14 (0.11) 2148.44 81–102
15.4 1928.41 (0.05) 1928.17 61–80
15.6 1478.05 (0.04) 1478.66 81–96
4923.6 (0.1) 4923.25 35–80 326
17.9 4847.06 (0.38) 4846.03 98–140 1ox
6150.38 (0.1) 6149.18 1–60
6167.3 (0.5) 6165.18 1–60 1ox
6472.55 (0.75) 6475.18 1–60 326
19.3 4958.66 (0.01) 4958.20 97–140
19.9 4288.74 (0.34) 4288.43 103–140
4830.5 (0.1) 4830.03 98–140
21.2 6434.93 (0.04) 6434.86 81–140 1ox
6451.22 (0.46) 6450.86 81–140 2ox
23.4 6418.65 (0.13) 6418.86 81–140
28.2 3434.52 (0.05) 3434.89 46–80
3760.8 (0.1) 3760.89 46–80 326
3664.32 (0.01) 3664.18 44–80
a Peptides are listed in order of retention times (RT).
b Experimental molecular masses determined by ESI-MS.
cMolecular masses calculated from aS amino acid sequence.
d The modified peptides are highlighted in bold.
Table 4
Chemical characterization of peptide species corresponding to the
peaks of the chromatogram relative to the fragmentation of aS/DHA
with GluC, after 70-min incubation, shown in Fig. 3B
RTa
Molecular mass (Da)
Peptide speciesdFoundb Calculatedc
min
4.5 703.21 (0.01) 703.39 29–35
5.2 607.21 (0.02) 607.25 136–140
10.8 859.52 (0.01) 859.48 21–28
11.7 970.36 (0.01) 970.36 124–131 1ox
1029.61 (0.01) 1030.39 115–123
1045.72 (0.02) 1046.39 115–123 1ox
1544.85 (0.01) 1544.85 21–35
12.5 615.46 (0.01) 615.32 14–20
12.8 1998.61 (0.02) 1998.74 115–131 2ox
12.9 1457.01 (0.01) 1456.79 14–28
13.2 954.35 (0.01) 954.36 124–131
1069.62 (0.01) 1070.42 132–140
13.3 1515.7 (0.1) 1514.76 1–13 2ox
1982.8 (0.1) 1982.74 115–131 1ox
2022.8 (0.1) 2022.77 124–140 1ox
13.7 1179.71 (0.02) 1179.65 36–46
2142.2 (0.1) 2142.16 14–35
13.8 912.32 (0.03) 912.46 106–114
1037.56 (0.01) 1037.55 47–57
2006.69 (0.02) 2006.77 124–140
14.2 2112.08 (0.01) 2112.07 1–20 2ox
14.3 1363.62 (0.02) 1363.56 47–57 326
2189.82 (0.51) 2190.13 84–105
15.8 3083.89 (0.03) 3084.57 84–114
19.3 2614.04 (0.05) 2613.43 58–83
20.8 2127.16 (0.01) 2127.15 62–83
29.3 3633.11 (0.11) 3632.97 47–83
29.5 4795.66 (0.02) 4794.61 36–83
a Peptides are listed in order of retention times (RT).
b Experimental molecular masses determined by ESI-MS.
cMolecular masses calculated from aS amino acid sequence.
d The modified peptides are highlighted in bold.
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ified (see “Discussion”). Thus, lacking the preferential site of
modification (His-50), it is reasonable to expect more than one
site to undergo modification with DHA, because potentially all
of the 15 Lys can be modified with the same chemical propen-
sity. To identify the site(s) of modification, a RP-HPLC fraction
enriched of the chemically modified H50Q with DHA was
digested by using endoproteinase GluC, using an enzyme to
substrate ratio of 1:50. The mixture was analyzed by RP-HPLC
(Fig. 5). As in the case of aS/DHA, peptides that containMet are
present also in oxidized form (Table 6). The smallest fragment
that has been found modified by DHA corresponds to the
sequence 58–83 (found mass 2939.7 Da, calculated 2613.98
326Da). This species contains 3 Lys residues (in position 58, 60,
and 80). Lys in position 60 is reported to be, after His-50, the
target of the reaction with 4HNE (38). However, we detected
more thanone adductwithDHA, therefore different lysines can
be involved.
Structural interaction with the fatty acids
Far UV-CD measurements were performed (Fig. 6), to cor-
relate the ability of the protein to be modified with their struc-
tural features deriving from the interaction with DHA. H50Q
and aS4ox maintain the property observed in aS to under-
go structural transition acquiring the -helical secondary
structure in the presence of the polyunsaturated fatty acid
(Fig. 6, A–C). Indeed, the characteristic signals at 208 and
222 nm in the far UV-CD spectra of the protein species in the
presence of DHA are visible. The acetylation of lysine resi-
dues and the N-terminal amino group causes the loss of this
ability and acetyl-aS remains unfolded in the presence of the
fatty acid (Fig. 6D). Interestingly, this correlates with the loss
of scavenger activity observed in Fig. 4C, whereas all the
other interacting species maintain their ability to slow down
DHA oxidation.
DHA and aS fibrils
MS spectra of DHA were recorded in the presence of pre-
formed WT aS fibrils (Fig. 7A). After 24 h of incubation (Fig.
7B), the mass/charge signals at 329.2, 351.2, and 367.2 are still
evident, but the presence of the signal atm/z 415.2 shows that
DHA undergoes partial oxidation. aS fibrils were further oxi-
dized as observed by MS analysis (not shown).
Figure 5. Fingerprinting analysis of modified H50Q by GluC. RP-HPLC
analysis of the proteolytic mixture of modified H50Q with DHA. The anal-
ysis was conducted on a Vydac C18 column (4.6  250 mm; The Separa-
tions Group, Hesperia, CA), eluted with a gradient of water, 0.1% TFA
versus acetonitrile, 0.085% TFA from 5 to 25% in 5 min, from 25 to 28% in
13min, from 28 to 39% in 3min, and from 39 to 45% in 21min at a flow rate
of 1 ml/min. The numbers close to the peaks refer to the main proteolytic
fragments. The sequence of the peptide containing the chemical modifi-
cation is reported.
Table 6
Chemical characterizationof fragments corresponding to thepeaksof
the chromatogram relative to the fragmentation of H50Q/DHA with
GluC shown in Fig. 5
RTa
Molecular mass (Da)
Peptide speciesdFoundb Calculatedc
min
10.6 859.5 (0.1) 859.48 21–28
11.6 1028.4 (0.1) 1028.55 47–57
1046.4 (0.2) 1046.39 115–123 1ox
1068.4 (0.2) 1070.42 132–140
970.4 (0.5) 970.36 124–131 1ox
12.3 615.3 (0.1) 615.32 14–20
12.9 1030.4 (0.1) 1030.39 115–123
1456.8 (0.2) 1456.79 14–28
1200.6 (0.2) 1199.46 131–140
13.1 954.4 (0.2) 954.36 124–131
1070.4 (0.1) 1070.42 132–140
13.5 1514.8 (0.1) 1514.83 47–61
13.7 1179.6 (0.1) 1179.65 36–46
1028.6 (0.1) 1028.55 47–57
14.1 912.5 (0.1) 912.46 106–114
15.0 2191.3 (0.5) 2190.19 36–57
15.3 2939.7 (0.2) 2940.48 58–83 326
15.8 3086.3 (0.1) 3086.41 84–114
16.8 1926.1 (0.9) 1924.84 106–123
18.8 4101.1 (0.8) 4099.46 84–123
19.4 2614.5 (0.1) 2614.98 58–83
21.1 2128.3 (0.5) 2127.15 62–83
29.5 5684.8 (0.8) 5683.37 58–114
30.1 4789.6 (0.9) 4788.48 36–83
30.3 3626.3 (0.5) 3626.12 47–83
37.9 9733.9 (1.1) 9729.97 47–140 2ox
38.5 8676.1 (0.5) 8676.56 47–131 2ox
39.8 6964.3 (1.5) 6961.89 36–105
7290.3 (1.1) 7287.89 36–105 326
40.3 6696.6 (1.1) 6696.42 58–123
a Peptides are listed in order of retention times (RT).
b Experimental molecular masses determined by ESI-MS.
cMolecular masses calculated from aS amino acid sequence.
d The modified peptides are highlighted in bold.
Table 5
Molecular masses of H50Q, aS4ox, and acetyl-aS in the presence of
DHA
Protein
Molecular mass (Da)
Protein speciesFounda Calculatedb
H50Q 14453.2 (0.1) 14451.1 H50Q
14468.7 (0.8) 14467.1  1ox
14485.2 (0.1) 14483.1  2ox
14780.3 (0.9) 14777.1  326
14795.3 (0.1) 14793.1  1ox 326
14811.1 (0.7) 14809.1  2ox 326
14826.7 (0.5) 14825.1  3ox 326
15100.5 (1.8) 15103.1  2 326
aS4ox 14525.1 (1.1) 14524.1 aS4ox
14542.1 (0.7) 14540.1  1ox
14836.1 (0.8) 14834.1  310
14852.8 (0.9) 14850.1 326
Acetyl-aS 14966.7 (1.1) 14964.4 12 acetyl
15009.5 (1.8) 15006.4 13 acetyl
15050.5 (2.1) 15048.4 14 acetyl
15092.1 (1.5) 15090.4 15 acetyl
15134.4 (1.6) 15132.4 16 acetyl
a Experimental molecular masses determined by ESI-MS.
bMolecular masses calculated from the amino acid sequence of aS species.
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Discussion
The relationship between aS and brain PUFAs is a debated,
but important question. It provides a link for the onset of PD
(39). In the presence of DHA andAA, aS undergoes deep struc-
tural changes, from the acquisition of stable secondary -heli-
cal structure to oligomerization or accelerated aggregation,
upon incubation, as a function of the ratio between the protein
and the fatty acid (27–29). Other consequences of this interac-
tion are the chemical modifications of the side chain of certain
residues, such as the oxidation of Met, the carbonylation, and
the formation of covalent adducts (28). In this work, we show
that His-50 is primarily modified in aS in the presence of
PUFAs, for the formation of a covalent adduct. This raises the
question if this effect would be specific and could be ascribable
to a sequestering ability of aS to capture free radicals, thus play-
ing a neuroprotective role in neurons in response to oxidative
stress and eventually preventing oxidation of unsaturated fatty
acids.
The process of unsaturated fatty acids peroxidation is a free-
radical chain reaction that consists of three partially overlap-
ping phases of radical reactions: initiation, propagation, and
termination (17) (Scheme 1). Initiation takes place by abstrac-
tion of a hydrogen radical from the PUFA (FAH). During the
propagation, the resulting lipid free radical (FA) reacts with
molecular oxygen to generate a peroxyl radical (FAOO), which
is the dominant radical present in the chain. It can react with
another FAH to form hydroperoxides (FAOOH) and FA, the
early products of autoxidation. Successively, the hydroperox-
ides may decompose in alkoxy (FAO) and hydro (HO) deriva-
tives. In vivo, the process is fostered by the high concentration
of the oxygen (at millimolar levels) in the lipid bilayer (40). In
vitro, the presence of tracemetals or sources of energy (i.e. light
or heat) can initiate the process (19). PUFAs easily undergo
autoxidation because of the intrinsic structure of the radical
intermediates, where electrons are highly delocalized. Normally,
such radicals can interact with proteins giving rise to a wide range
of compounds able to affectmany physiological events (41). Here,
we show that the propagation chain reaction is hampered in the
presence of aS, and mutually, the protein results chemically
modified with the formation of covalent adducts.
Fingerprinting analysis of the modified species and relative
reactivities toward oxidative modifications suggested that the
residue that is likely modified in aS is His-50. These data agree
with the specific reactivity of lipid peroxidation products, such
as allylic radicals, which involve preferentially in the order cys-
teine (absent in aS), histidine and lysine residues (42), and
4HNE, which, in aS, involves specifically His-50 (43). The im-
idazole moiety is nucleophilic and can react with one of the
early products of autoxidation of DHA or AA. The propagation
step in the PUFAs oxidation is hampered and the consequent
breakdown into lipid-derived aldehydes and ketones is avoided,
indeed, under our experimental conditions, the reaction termi-
nates with the sequestration of the DHA or AA early reactive
species by aS and the formation of a 4-hydroxy-2(E)-nonenal
moiety was not observed.
Interestingly, Zhu et al. (44) proposed for aS an antioxidant
activity of protection of lipids in neuronal membranes. They
suggested a mechanism mediated by the four Met residues.
This fact is corroborated by the finding that oxidizedMet(s) can
be repaired in vivo by intracellular methionine sulfoxide reduc-
tase (45). Our data show that the scavenging activity of DHA
radicals is not exclusively correlated to Met residues, because
aS4ox is still able to sequester these radicals. In view of the fact
that His-50 is the only His residue in aS and, chemically, the
preferential modification site by lipid radicals (42), the impor-
tance of this residue in the scavenger activity was investigated
by using a natural aS variant containing a Gln instead of His in
position 50 (H50Q) (34–36). We showed that, despite the lack
of His-50, this variant is able to protect DHA. The behavior of
H50Q in the presence of DHA is very similar to that of WT aS,
and the protein acquires -helical secondary structure upon
incubation with DHA. It was recently found that the H50Q
mutation does not affect aS subcellular localization, the struc-
ture of free or membrane-bound aS monomer nor its capacity
Figure 6. Structural analysis by CD. Far UV CD spectra of aS (A), H50Q (B),
aS4ox (C), and acetyl-aS (D), in the absence (dashed line) and presence (solid
line) of DHA (P/DHA, 1:50). The spectra were recorded in PBS buffer, pH 7.4,
using a 1-mm path length quartz cell and a protein concentration of 5–7 M.
Figure 7.DHAandaS fibrils.Positive ESI-MS spectra ofDHA recorded after 0
(A) and 24h (B) at 37 °C and 500 rpm in the presence of preformed fibrils of aS.
Fibrils are added to realize a protein to fatty acid ratio of 1:50.
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to be phosphorylated in vitro (46). Moreover, the substitution
of His-50 with Gln accelerates the conversion of aS into
-sheet-rich oligomers (35) and increases aS secretion and
extracellular toxicity (46). If incubated with DHA, H50Q is
modified and a mass increase of 326 Da (or a multiple of it) is
still detectable, indicating the formationof covalent adduct(s)with
the fatty acid. LackingHis, themodifications can reasonably occur
at the level of the lysine residues, which, as nucleophiles, are vul-
nerable to modification by lipid peroxidation-derived electro-
philes (42). A possible candidate is Lys in position 60 that was
reportedmodified in the presence of 4HNE (38).
Our data show also that the structural interaction is an
important requisite for aS scavenger activity. The analysis of the
structural properties of aS4ox by CD studies has shown that the
presence of methionine sulfoxide does not alter the ability of aS
to acquire -helical secondary structure upon interaction with
DHA, as already observed with other lipids (30). On the con-
trary, the extensive acetylation does not allow any interaction
with the fatty acid and acetyl-aS does not sequester DHA radi-
cals. This behavior suggests an important role for Lys residues
in the repeats of aS.
A further consideration can be done on the ability of aS fibrils
to partially protect DHA. The fold of aS fibrils comprises a
central core of cross- structure (residues 35–94 according to
Vilar et al. (47), and residues 38–96 according toComellas et al.
(48) flanked by flexible regions. In bothmodels, the N-terminal
domain containing the first and second repeats is not engaged
in the fibril structure. Zarbiv et al. (49) demonstrated that ly-
sines belonging to these repeats are essential for lipid interac-
tion. Therefore, aS fibrils could still interact with DHA. The
reduced activity could be due to the fact that not the entire
N-terminal region, but likely only the first 25 residues, not
engaged in the structure of fibril, are suitable for lipid interac-
tion. This is consistent with the observation that the first 25
residues have the highest membrane affinity (50), with amino
acids 6–25 likely firmly anchored to the membrane (51). Com-
paring the spectra of DHA obtained in the presence of aS as a
monomer and aS as fibril, just evaluating the height of the sig-
nals atm/z 415 in a ratio with those due to not oxidized DHA,
roughly fibrils lose 80% of the scavenging activity of aS. It is not
unexpected that aS, accumulating as fibrils in Lewy bodies, does
not maintain the scavenging activity. In vivo, fibrils formation
could be further detrimental, because it is known that mono-
meric aS decreases in PD (52), probably captured by the fibrillar
aggregates.
In our previous works, we have shown that aS and its N-ter-
minal fragments (such as 1–52) reduce the aggregative concen-
tration ofDHAand cause a resizing of the lipid oil droplets with
formation of amicroemulsion (27, 53). In aqueous buffer, DHA
forms an emulsion and shows a strong tendency to oxidize,
generating monohydroxides and dihydroperoxides derivatives.
In a bulk phase or in an inorganic solvent, this tendency is
partially reduced (54). According to Miyashita (54), we can
hypothesize that aS protects the fatty acid from oxidation act-
ing also as an emulsifier. Indeed, when aS is not able to interact
with lipids or even to resize the fatty acid droplets, no oxidant
scavenger effect is observable. This is evident with acetyl-aS
that lost the ability to interact with DHA (Fig. 6) and to resize
DHA droplets (data not shown). However, aS does not behave
as an inert emulsifier, but it undergoes oxidative modifications.
Upon interaction with DHA, aS acquires a conformation that
promotes its oxidation serving as terminal of the lipid oxidation
process.
Several studies reported that aS is involved in the mainte-
nance of the correct levels of PUFAs (55). It was also proposed
that aS may play a protective role of neurons exposed to oxida-
tive stress preventing oxidation of PUFAs (33). Indeed, lipid
peroxidation increases with aging and is linked to PD (21). In
neurons exposed to oxidative stress or obtained from patients
affected by PD, the levels of PUFAs in a non-esterified form
were found higher than normal (15). Interestingly, it was also
reported that in cultured cells a PUFA treatment induces the
appearance of toxic aS oligomers (56). Soluble oligomers are
also triggered by oxidation of aS Met residues (57). In vivo,
methionine sulfoxides are repaired by intracellular reductase.
Very recently, it was observed that when the two C-terminal
Met are not efficiently repaired by endogenous cellular
enzymes, they remain oxidized. This results in the accumula-
tion of oxidized aS, with high tendency to form oligomers, and
that shows impaired phosphorylation (58). The cellular impact
of this depends on the eventual toxicity of the oligomeric spe-
cies. If toxic oligomers accumulate in cells, the formation of
oxidized or partially oxidized aS becomes a significant contrib-
uting factor to PD. The protective role of aS toward PUFAs and
the tendency of the protein to aggregate in their presence are
apparently conflicting. Therefore, it is plausible to speculate
that the protein/PUFAs ratio is a discriminant factor determin-
ing the effect of the interaction between aS and PUFAs. Under
physiological conditions, aS can participate actively to the con-
trol of oxidative homeostasis of the intracellular environment,
protecting the free fatty acids from oxidation and maintaining
their correct level. Environmental factors can affect this equi-
librium, by either increasing oxidative stress or changing DHA
concentration. PD has been previously linked to oxidative
stress, which can increase lipid oxidative species to an extent
that does not allow the normal biological turnover of aS, leading
to the accumulation of modified protein and to increased pro-
pensity to its oligomerization.Moreover, also theDHAconcen-
tration has been reported to increase in neuronalmembranes of
PD patients and also in general aging (55). Higher concentra-
tions of DHA prevents aS amyloid aggregation, probably by the
-helix structure acquisition, but the formation of stable toxic
oligomers is observed (27–29, 55). Because oligomers might
represent the most toxic species, the increased DHA concen-
tration in the cell could accelerate toxicity rather than having a
protective role. Otherwise, we found that fibrils, in comparison
to soluble aS, have a reduced scavenging activity. Determina-
tion of the real intracellular proportion between soluble and
fibrillar aS will allow in the future to properly frame these find-
ings within the complexity of the pathophysiology of the
disease.
In conclusion, aS sequence is tailored to efficiently exert an
oxidant scavenger activity, accordingly with recent hypothesis
(33). The role of Met has been extensively described (30, 45).
Lysine residues could play a significant role. Their distribution
makes the aS interaction with PUFAs and other lipids effective.
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This deep interaction has specific consequences on the physical
state of PUFAs, which are emulsified and resized as well as on
the reactive species that are sequestered. Lysine and histidine
residues can mediate the capturing action for its intrinsic
chemical reactivity, hampering the propagation of the PUFAs
oxidation process. This proposed scavengingmechanism could
not be assumed as specific of aS. Its biological significance
resides in the recognized role of the protein in PD, and spe-
cifically in the reported evidences of its interaction with
PUFA and its involvement in their metabolism (11–16). aS is
mainly a presynaptic protein, and it has been reported to be
able to bind plasma membranes, lipid rafts, inner nuclear
membrane, and mitochondrial membranes. These interac-
tions are considered critical for the physiological function of
aS (10). DHA is an essential PUFA, fundamental for the func-
tions and maintenance of the nervous system, and deficits in
DHA are associated with cognitive decline during aging and
in neurodegenerative disease (59). aS has been repeatedly
reported to interact with PUFA: endogenous cytosolic levels
of aS can buffer arachidonic acid affecting SNARE assembly
on cellular membrane (60). Elevated PUFA levels have been
detected in PD or Lewy body dementia-affected human
brains, whereas the levels of certain PUFAs were decreased
in the brains of mice genetically deleted of aS (55). This
mechanism of scavenging activity could provide a link
between aS, altered lipid composition in neurodegenerative
disorders, and PD development.
Experimental procedures
Protein expression and purification
Expression and purification of recombinant aS and aS variant
were obtained as previously described (29, 35). Protein con-
centrations were determined by absorption measurements
at 280 nm using a double-beam Lambda-20 spectrophotom-
eter from PerkinElmer Life Sciences. The extinction coeffi-
cient for aS and H50Q at 280 nm was 5960 M1 cm1 (61).
DHA and AA were purchased from Sigma. All other chemi-
cals were of analytical reagent grade and were obtained from
Sigma or Fluka (Buchs, Switzerland). Aliquots of DHA and
AA were stored at a concentration of 76 mM in 100% ethanol
at 80 °C under a helium atmosphere to prevent oxidation.
Fibrils were obtained after 2 weeks of incubation of aS in PBS
buffer, pH 7.4, using a protein concentration of 70 M, at
37 °C under shaking (500 rpm). To isolate fibrils frommono-
mers, the protein sample was ultracentrifuged at 380,000 g
for 1 h at 4 °C.
Chemical modification of lysine andmethionine residues in aS
The oxidation of the four Met residues was obtained using a
method described in Uversky et al. (62). Briefly the protein was
suspended in 20mM phosphate buffer, 100mMNaCl, pH 7, at a
protein concentration of 3 mg/ml and H2O2 was added to a
final concentration of 4% (v/v). The reaction was kept at
room temperature for 20 min. The acetylation of Lys was
performed according to Means and Feeney (63). aS was sus-
pended in a 1:1 solution of water and saturated sodium ace-
tate (protein final concentration 7.5 mg/ml), cooled in an
ice-bath and treated with a total amount of acetic anhydride
approximately equivalent to the weight of the protein, grad-
ually added in 1 h. The solution was maintained at pH 8.5.
The reagents were removed by using a centrifugal filter
device (Amicon Ultra 10K,Millipore). The reactionmixtures
were purified by RP-HPLC and the chemical modifications
were verified by ESI-MS.
Mass spectrometry
DHA and AA samples were analyzed by ESI-mass spectrom-
etry (direct injection or upon purification in RP-HPLC) in the
absence or in the presence of different protein species ([pro-
tein], 50M): aS, the variantH50Q, tetraoxidized aS (at the level
of Met residues), and alkylated aS (at the level of Lys residues).
The reactionwas conducted in 20mMphosphate buffer, pH7.0,
by using a molar protein/lipid ratio of 1:50, in which all aS
molecules were bound to DHA and in -helical conformation
(27). DHAunder this condition forms oil droplets, as previously
reported (27). Aliquots of the solution after preparation and
24hof incubation (37 °C, 300 rpm)were diluted 10 times in 50%
H2O, 49.9% acetonitrile, 0.1% HCOOH, and analyzed by an
ESI-mass spectrometer with a Q-TOF analyzer (Micro) from
Waters (Manchester, UK). Themeasurements were conducted
at a capillary voltage of 2.7 kV and a cone voltage of 35 V. The
molecular masses of protein samples were estimated using the
Mass-Lynx software 4.1 (Micromass).
CD spectroscopy
Circular dichroism (CD) spectra in the far UVwere recorded
on a Jasco J-710 spectropolarimeter (Tokyo, Japan), using a
1-mm path length quartz cell and a protein concentration of
5–7M. Themean residue ellipticity []MRW (deg cm2 dmol1)
was calculated from the formula []MRW (obs/10) (MRW/lc),
where obs is the observed ellipticity in deg, MRW is the mean
residue molecular weight of the protein, l the optical path
length in cm, and c the protein concentration in g/ml. The spec-
tra were recorded in PBS buffer, pH 7.4.
Fingerprinting analysis
Proteolysis with trypsin was conducted using an E/S ratio
of 1:100 (by weight), in PBS, pH 7.4, and the reaction was
quenched by acidification with TFA in water (4%, v/v). Prote-
olysis with endoproteinase GluC was performed at E/S ratio of
1:50 (by weight). RP-HPLCof proteolyticmixturewas conducted
on a Vydac C18 column (4.6 250 mm; The Separations Group,
Hesperia, CA), eluted with a gradient of water, 0.1% TFA versus
acetonitrile, 0.085%TFA from5 to25% in5min, from25 to28% in
13min, from 28 to 39% in 3min, and from 39 to 45% in 21min at
a flow rateof 1ml/min.Thepeptideswere identifiedbymass spec-
trometry. MS-MS analysis was conducted on the selected ions
using collision energies from 15 to 30 V.
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